|A Brief Guide to Pharmacogenetics and Pain Management|
September 25, 2013
This webinar will examine the genetic basis for differences in clinical responses observed among patients receiving opioid analgesics. Mutations in genes encoding the mu opioid receptor have been linked to the variability in responses to opioids. Other genetic polymorphisms affect the bioavailability and metabolic disposition of opioids and their metabolites. Pharmacogenetic studies also have provided a molecular foundation supporting opioid rotation in cases where efficacy diminishes or intolerable side effects occur. As genetic findings on specific opioid analgesics are extended, clinicians will be better positioned to identify from the outset which opioid analgesic may be most appropriate for an individual patient.
Charles E. Argoff, M.D.
The content of this activity does not relate to any product of a commercial interest.
|Add To Cart|